

Press Release

Frauenfeld, Switzerland, 2024

Thomas Kraft becomes the new CEO of SIS Medical AG as of September 2024

SIS Medical AG (Swiss Interventional Systems), a leading medical technology firm in the field of interventional cardiology that provides effective product solutions for demanding and complex lesion preparations, is appointing Dr Thomas Kraft as its Chief Executive Officer as of September 2024. “In collaboration with the SIS Medical team, he will launch the next phase in the company’s growth and drive forward its expansion into new, international markets such as the US,” explains Hanns-Peter Knaebel, Chairman of the Board of Directors. Kraft replaces Sergej Kammerzell, who has left the company in August 2024. “Sergej Kammerzell assisted SIS Medical and supported its evolution during a decisive period, for which we are very grateful. We wish him all the best for the next steps in his career,” Hanns-Peter Knaebel continued.

Thomas Kraft has 22 years of international experience in the medical technology industry. During this time, his responsibilities have included various management roles at BIOTRONIK, the B. Braun division at Aesculap, at Stryker and most recently as CEO of Resuscitec. Over the past decade he ran different businesses within the heart and interventional cardiology field. Dr. Kraft completed his studies in economics at the University of Hanover, wrote his doctorate on lean management in hospitals and has participated in various executive management programmes. Thomas Kraft lives with his family on Lake Constance, after spending several years abroad.

“We are very pleased to welcome Thomas Kraft as our new CEO,” says Uwe Steinbacher, member of the Board of Directors and partner at the investor SHS. “In addition to his proven track record, his management and leadership experience from corporate structures of all sizes will enable the successful development of our team and organization further on.”

“I would like to thank our Board of Directors for placing their trust in me; I am very pleased to be working with the team at SIS Medical. Together, we will establish our strong product solutions as standard of care, becoming an international medical device organization, made in Switzerland,” says Thomas Kraft.

About SIS Medical

SIS Medical AG, based in Frauenfeld, Switzerland, is a leading Swiss developer, manufacturer and distributor of high-performance products for interventional arterial diseases. The company is known for its main product “OPN NC – Super High Pressure PTCA Balloon”, for the treatment of calcified and severely calcified lesions and in-stent restenosis.

www.sis-medical.com

The company is privately owned and the main shareholder, SHS Gesellschaft für Beteiligungsmanagement mbH (www.shs-capital.eu), based in Tübingen, Germany.

SIS Medical AG

Hungerbühlstrasse 12a | CH-8500 Frauenfeld | Phone +41 52 245 09 90 | info@sis-medical.com
www.sis-medical.com